RGD肽與腫瘤診治的研究進展_《中國普外基礎與臨床雜志》

作者：

杜果城 , 吳誠義

重慶醫科大學附屬第一醫院普外科（重慶400016）;

關鍵詞：

精氨酸-甘氨酸-天冬氨酸肽整和素腫瘤診斷腫瘤治療

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的介紹精氨酸-甘氨酸-天冬氨酸（RGD）肽在腫瘤診治領域的研究現狀、價值及發展前景。
方法對RGD肽在腫瘤診治領域的實驗研究新進展進行綜述。
結果 RGD肽存在于多種生物細胞外基質中，能特異性識別細胞表面整和素并與之結合，從而介導多種重要的生命活動。外源性RGD肽與腫瘤細胞表面整和素結合后，可作為體內RGD肽類物質的競爭性抑制劑，從而能抑制腫瘤細胞與細胞外基質的黏附與遷移、抑制腫瘤血管形成、誘導腫瘤細胞凋亡，且具有靶向性標記腫瘤顯像以及與其他方法聯合治療腫瘤的潛在價值。
結論 RGD肽能從多個環節對腫瘤起到抑制作用，且展示出與其他療法聯合治療腫瘤的前景。

引用本文： 杜果城,吳誠義. RGD肽與腫瘤診治的研究進展. 中國普外基礎與臨床雜志, 2004, 11(6): 558-560. doi: 復制

1.	11Kang IC, Kim DS, Jang Y, et al. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis [J]. Biochem Biophys Res Commun， 2000; 275(1)∶169 12Anuradha CD, Kanno S, Hirano S. RGD peptideinduced apoptosis in human leukemia HL60 cells requires caspase3 activation [J]. Cell Biol Toxicol， 2000; 16(5)∶275.
2.	Allen CM, Sharman WM, La Madeleine C, et al. Attenuation of photodynamically induced apoptosis by an RGD containing peptide [J]. Photochem Photobiol Sci, 2002; 1(4)∶246.
3.	Chavakis E, Riecke B, Lin J, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides [J]. Diabetologia, 2002; 45(2)∶262.
4.	Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting [J]. Cancer Biother Radiopharm， 2002; 17(6)∶641.
5.	Schraa AJ, Kok RJ, Moorlag HE, et al. Targeting of RGDmodified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study [J]. Int J Cancer， 2002; 102(5)∶469.
6.	Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities [J]. Prep Biochem Biotechnol， 2002; 32(4)∶363.
7.	Richards J, Miller M, Abend J, et al. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin [J]. J Mol Biol， 2003; 326(5)∶1475.
8.	Humphries MJ, Mould AP. Structure. An anthropomorphic integrin [J]. Science， 2001; 294(5541)∶316.
9.	Su ZF, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a Technetium99mlabeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging [J]. Bioconjug Chem， 2002; 13(3)∶561.
10.	Su ZF, He J, Rusckowski M, et al. In vitro cell studies of technetium99m labeled RGDHYNIC peptide, a comparison of tricine and EDDA as coligands [J]. Nucl Med Biol， 2003; 30(2)∶141.
11.	Madeja Z, Sroka J. Contact guidance of Walker carcinosarcoma cells by the underlying normal fibroblasts is inhibited by RGDcontaining synthetic peptides [J]. Folia Histochem Cytobiol， 2002; 40(3)∶251.
12.	Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase3 activation [J]. Nature， 1999; 397(6719)∶534.
13.	Kok RJ, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGDmodified proteins as alpha(v)beta(3) integrin directed therapeutics [J]. Bioconjug Chem， 2002; 13(1)∶128.
14.	Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alphanu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo [J]. Br J Cancer， 2002; 86(5)∶788.
15.	Zygmunt M, Herr F, KellerSchoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor [J]. J Clin Endocrinol Metab， 2002; 87(11)∶5290.
16.	de Groot FM, Broxterman HJ, Adams HP, et al. Design, synthesis, and biological evaluation of a dual tumorspecific motive containing integrintargeted plasmincleavable doxorubicin prodrug [J]. Mol Cancer Ther， 2002; 1(11)∶901.
17.	Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts [J]. Cancer Res, 2002; 62(15)∶4263.
18.	Burke PA, DeNardo SJ, Miers LA,et al. Combined modality radioimmunotherapy. Promise and peril [J]. Cancer， 2002; 94(4 Suppl)∶1320.

1. 11Kang IC, Kim DS, Jang Y, et al. Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis [J]. Biochem Biophys Res Commun， 2000; 275(1)∶169 12Anuradha CD, Kanno S, Hirano S. RGD peptideinduced apoptosis in human leukemia HL60 cells requires caspase3 activation [J]. Cell Biol Toxicol， 2000; 16(5)∶275.
2. Allen CM, Sharman WM, La Madeleine C, et al. Attenuation of photodynamically induced apoptosis by an RGD containing peptide [J]. Photochem Photobiol Sci, 2002; 1(4)∶246.
3. Chavakis E, Riecke B, Lin J, et al. Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides [J]. Diabetologia, 2002; 45(2)∶262.
4. Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting [J]. Cancer Biother Radiopharm， 2002; 17(6)∶641.
5. Schraa AJ, Kok RJ, Moorlag HE, et al. Targeting of RGDmodified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study [J]. Int J Cancer， 2002; 102(5)∶469.
6. Zhao M, Wang C, Jiang X, et al. Synthesis of RGD containing peptides and their bioactivities [J]. Prep Biochem Biotechnol， 2002; 32(4)∶363.
7. Richards J, Miller M, Abend J, et al. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin [J]. J Mol Biol， 2003; 326(5)∶1475.
8. Humphries MJ, Mould AP. Structure. An anthropomorphic integrin [J]. Science， 2001; 294(5541)∶316.
9. Su ZF, Liu G, Gupta S, et al. In vitro and in vivo evaluation of a Technetium99mlabeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging [J]. Bioconjug Chem， 2002; 13(3)∶561.
10. Su ZF, He J, Rusckowski M, et al. In vitro cell studies of technetium99m labeled RGDHYNIC peptide, a comparison of tricine and EDDA as coligands [J]. Nucl Med Biol， 2003; 30(2)∶141.
11. Madeja Z, Sroka J. Contact guidance of Walker carcinosarcoma cells by the underlying normal fibroblasts is inhibited by RGDcontaining synthetic peptides [J]. Folia Histochem Cytobiol， 2002; 40(3)∶251.
12. Buckley CD, Pilling D, Henriquez NV, et al. RGD peptides induce apoptosis by direct caspase3 activation [J]. Nature， 1999; 397(6719)∶534.
13. Kok RJ, Schraa AJ, Bos EJ, et al. Preparation and functional evaluation of RGDmodified proteins as alpha(v)beta(3) integrin directed therapeutics [J]. Bioconjug Chem， 2002; 13(1)∶128.
14. Buerkle MA, Pahernik SA, Sutter A, et al. Inhibition of the alphanu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo [J]. Br J Cancer， 2002; 86(5)∶788.
15. Zygmunt M, Herr F, KellerSchoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor [J]. J Clin Endocrinol Metab， 2002; 87(11)∶5290.
16. de Groot FM, Broxterman HJ, Adams HP, et al. Design, synthesis, and biological evaluation of a dual tumorspecific motive containing integrintargeted plasmincleavable doxorubicin prodrug [J]. Mol Cancer Ther， 2002; 1(11)∶901.
17. Burke PA, DeNardo SJ, Miers LA, et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts [J]. Cancer Res, 2002; 62(15)∶4263.
18. Burke PA, DeNardo SJ, Miers LA,et al. Combined modality radioimmunotherapy. Promise and peril [J]. Cancer， 2002; 94(4 Suppl)∶1320.

《中國普外基礎與臨床雜志》

RGD肽與腫瘤診治的研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

RGD肽與腫瘤診治的研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料